CliffBio
biologic

Rebif

interferon beta-1a

Loss of exclusivityDecember 2024projected — 12-year biologic exclusivity estimate
CompanyEMD Serono →See this company's full patent-cliff portfolio

Drug detail

Brand nameRebif
Active ingredientinterferon beta-1a
Strength8.8MCG/0.2ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalDecember 2012
Marketing statusRx

More from EMD Serono

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Rebif patent cliff — loss of exclusivity December 2024 | CliffBio